Tiziana Life Sciences Presents Phase 2a ALS Trial Data at ALS Nexus 2026 — Tiziana Life Sciences Ltd.

Event summary

Tiziana Life Sciences presented Phase 2a BANYAN trial data for intranasal foralumab at ALS Nexus 2026 on August 24, 2026.
The BANYAN trial is a 3:1 (foralumab: placebo) randomized, placebo-controlled, multicenter study evaluating safety, biomarkers, and early clinical effects in ALS patients.
The trial is supported by grants from the ALS Association, Martha Olson-Fernandez Foundation, and ALS Bridge Foundation.
Foralumab aims to modulate the Treg pathway, addressing neuroinflammation and microglial activation in ALS.
The trial is currently in operational startup phase, with enrollment timing and site locations to be announced.

The big picture

Tiziana's focus on intranasal foralumab represents a strategic pivot toward non-invasive immunomodulation for neurodegenerative diseases. The BANYAN trial's success could validate the Treg pathway as a critical target in ALS, potentially opening new avenues for treatment. The company's ability to leverage existing infrastructure through the Healey ALS MyMatch program reduces operational risk but also ties its fate to the broader ALS research ecosystem.

What we're watching

Trial Execution: The pace at which the BANYAN trial enrolls and progresses will determine the timeline for interim data readouts.
Regulatory Pathway: Whether the intranasal foralumab approach can secure regulatory approval for ALS, given its novel mechanism.
Competitive Positioning: How Tiziana differentiates foralumab in the crowded ALS therapeutic landscape, particularly against other immunomodulatory approaches.